CJC-1295 DAC Protocol: How to Cycle It, Timing & What to Expect

Protocol snapshot

• Typical cycle length: 8 to 12 weeks, with an optional extension to 16 weeks; followed by a 4 to 6 week off-cycle break
• Frequency: Twice weekly, spaced 3 to 4 days apart (for example Monday and Thursday); some protocols use once weekly
• Common delivery routes: Subcutaneous injection (a small injection just under the skin)
• Key timing notes: Inject in a fasted state, ideally in the evening to align with the body's natural GH rhythm during sleep; exact clock timing is forgiving given the compound's long half-life

Who This Protocol Is For

CJC-1295 DAC draws interest from people pursuing goals tied to the growth hormone axis: body composition changes, accelerated recovery from training or injury, and longer-term efforts related to healthy aging and tissue support. The compound stimulates the pituitary gland to produce more growth hormone, which in turn drives IGF-1 production from the liver. Those downstream effects are what make it relevant to a fairly wide range of goals.

The most common reasons people look into a CJC-1295 DAC protocol include improving recovery between training sessions, supporting fat metabolism alongside resistance training, and addressing chronic injury situations where enhanced tissue repair is the priority. Some users approach it as part of a longevity-oriented stack, while others are primarily after the body composition shift that sustained GH elevation can produce over a full cycle.

Experience level matters here more than it does with some other peptides. It shapes the protocol in a meaningful way. Newer users typically start at the lower end of the titration range and move more slowly through the ramp-up phase. More experienced users who have run GH-axis peptides before may progress through titration faster. They are also more attuned to the early signals that indicate whether a per-injection amount is sitting in a tolerable range.

The DAC version specifically suits people who want a less frequent injection schedule. The compound's albumin-binding modification extends its half-life to roughly 6 to 8 days. That means twice-weekly injections maintain consistent coverage rather than requiring daily dosing. That convenience comes with a meaningful trade-off: if side effects emerge, the compound cannot be cleared quickly. Anyone considering the DAC version should understand that each injection is a week-plus commitment, which is a different risk profile than a peptide that clears in a few hours.

Delivery route is straightforward for CJC-1295 DAC: subcutaneous injection is the established route. The compound has not been validated for oral or other non-injectable use, so delivery-route preference does not offer alternatives here the way it does with some other peptides.

How Is a CJC-1295 DAC Cycle Structured?

A CJC-1295 DAC cycle has a recognizable shape that is worth understanding before getting into the details of any individual phase. The cycle opens with a gradual ramp-up period across the first several weeks, where the per-injection amount steps up incrementally every two weeks rather than starting at the full maintenance level. That ramp-up transitions into a steady maintenance window that carries through the rest of the active cycle. The full cycle then closes with an off-cycle break before any subsequent run.

Standard cycles run 8 to 12 weeks in the active phase, with some practitioners extending to 16 weeks. That range sits longer than many peptide protocols, which reflects how the compound works: because each injection stays active for roughly a week, GH and IGF-1 levels build cumulatively over the cycle rather than resetting between doses. The effect continues to develop across the first weeks and reaches a more stable plateau during the maintenance window.

One feature worth naming upfront is what makes this ramp-up different from a traditional loading phase. In many peptide protocols, a loading phase means a higher initial dose that drops to a lower maintenance level. Here the movement is the opposite: start lower and step upward, giving the body time to adapt to continuous GH elevation before arriving at the maintenance level. The full mechanics of that titration and what each phase accomplishes are covered in the Loading and Maintenance Phases section below.

How Your Dose Is Determined

What moves a CJC-1295 DAC dose:

• Your goal: Recovery-focused and longevity-oriented protocols tend to settle toward the lower end of the range, where the GH elevation is meaningful but more moderate. Body composition goals or more intensive recovery demands tend to sit higher. The distinction is less about dramatically different dose levels and more about where within the range makes sense for the purpose.
• Experience level: Users newer to GH-axis peptides typically move through the titration ramp more slowly and land at a lower maintenance level than experienced users who have run similar compounds before. The titration structure accommodates this directly, with incremental steps rather than a fixed starting point for everyone.
• Delivery route: CJC-1295 DAC is run subcutaneously, and that is the only well-established route. Unlike peptides that offer oral or nasal alternatives with different dose logic, there is no route-based dose variation to navigate here. The relevant variables are the per-injection amount and frequency, both of which the titration schedule addresses.
• Individual response: Two people with identical goals and similar experience levels can land in different places on the range based on how their GH axis responds. Flushing, water retention, and sleep disruption are common signals that a given level may be running toward the higher end of individual tolerance, and those signals typically prompt holding at the current titration step longer rather than moving up.

The titration approach matters more with CJC-1295 DAC than with most peptides precisely because of the long half-life. If a per-injection amount is too high, that experience plays out over a week or more per injection rather than clearing in a few hours. That irreversibility is why protocols emphasize stepping up gradually and responding to tolerability signals rather than rushing to the maintenance level.

There is no single dose that fits everyone, which is exactly what the app accounts for.

Your dose should not be a guess. The MyPeptidePal Protocol Creator takes your specific goal, your experience with GH-axis peptides, and where you land on the titration ramp and builds your CJC-1295 DAC protocol: your dose, your cycle, and your timing.

Get your protocol at mypeptidepal.ai

How Often Do You Take CJC-1295 DAC?

The standard frequency is twice weekly, with injections spaced 3 to 4 days apart. A Monday and Thursday pattern, or Tuesday and Friday, achieves that spacing cleanly. Some protocols use once weekly, though twice weekly is more commonly cited in both practitioner and community sources for the active phase of the cycle.

The half-life of roughly 6 to 8 days is what makes twice-weekly dosing work. Each injection keeps the compound active in the body for well over a week, so two injections per week maintain a steady level of GH stimulation without requiring daily administration. This is a meaningful departure from non-DAC GHRH peptides, which clear in under an hour and require multiple daily injections to maintain coverage. The DAC modification trades injection frequency for a longer commitment per dose, which is the core appeal of this formulation for many users.

On timing, the consensus from practitioner protocols is to inject in a fasted state, with a window of roughly 90 to 120 minutes without food before the injection and at least 30 to 60 minutes before eating again. The reasoning is straightforward: carbohydrate intake and the resulting insulin spike blunt GH signaling, so injecting in a fed state reduces the effective yield of each dose. Evening injection, before sleep, aligns the dose with the body's natural GH pulse pattern during deep sleep and is the most commonly cited timing preference.

Because of the long half-life, exact clock timing is far less critical than it is with short-acting peptides. The fasted-state principle matters more than hitting a precise time of day. One practical note: because some users report sleep disruption as the cycle progresses, particularly later in longer cycles, a number of users who start with evening injections shift to morning administration if nighttime effects become disruptive.

Loading and Maintenance Phases

CJC-1295 DAC does not follow the classic loading-phase structure where a higher initial dose is used to saturate the system quickly. The protocol opens with a lower per-injection amount and steps upward incrementally over the first six weeks, reaching the maintenance level around week seven. Think of it less like a loading phase and more like a calibrated ramp, where the body's adaptation to continuous GH elevation is built gradually rather than demanded all at once.

The ramp-up moves in incremental steps every two weeks. The first two weeks use the lowest per-injection amount; weeks three and four step up to a moderate level; weeks five and six step up again before arriving at the maintenance window that carries through the rest of the cycle. Each step functions as a tolerance check before progressing. If a given step produces strong flushing, pronounced water retention, or sleep disruption, the standard response is to hold at that level longer rather than advancing on the standard schedule.

The maintenance phase runs from approximately week seven through the end of the cycle. This is the window where the most meaningful effects accumulate: stable GH and IGF-1 elevation, consistent recovery improvement, and the body composition changes associated with sustained GH stimulation. Because each injection remains active for roughly a week, the maintenance phase is defined by a continuous, steady GH elevation rather than the pulsatile peaks that characterize endogenous GH release or non-DAC GHRH peptides.

One practical consequence of the long half-life during maintenance: a missed injection is not a crisis, since the compound from the previous injection is still circulating and active. The full guidance on handling a missed dose lives in the Common Protocol Mistakes section.

Off-Cycle Considerations

Off-cycle breaks are standard and well-established for CJC-1295 DAC, and the rationale is more substantive than it is for many peptides. A 4 to 6 week break follows each active cycle, and this is not simply a precautionary convention. It serves three distinct physiological purposes tied directly to how the compound works.

The first is receptor resetting. Continuous GH receptor stimulation leads to desensitization over time, a process where the pituitary's receptors progressively respond less strongly to the same signal. A 4 to 6 week break gives those receptors time to regain sensitivity, preserving the efficacy of subsequent cycles. Running continuously does not produce more benefit; it tends to produce diminishing returns and a blunted response in later cycles.

The second purpose is hormone normalization. After an active cycle, both GH and IGF-1 levels remain elevated for some time beyond the last injection, reflecting the long half-life. The off-cycle period allows those levels to return toward baseline. Prolonged exposure to hormone levels above the body's natural range carries metabolic health implications and is one of the core reasons the break is considered standard rather than optional.

The third is antibody management. The DAC modification allows the peptide to bind to albumin in the bloodstream, and this mechanism may trigger antibody formation over longer periods of use. Extended breaks are thought to reduce the risk of immunological sensitization that can develop with prolonged continuous use.

CJC-1295 DAC is not FDA-approved for human use, and it is prohibited both in and out of competition under the WADA S2 category, which covers peptide hormones, growth factors, and related substances. Athletes subject to drug testing should be aware that use at any point in the calendar year carries sanctioning risk.

What to Expect Week by Week

The timeline for CJC-1295 DAC is more gradual than many users expect, which is consistent with how the compound works. Continuous GH elevation builds cumulatively rather than producing an immediate pronounced effect, so the early weeks are often subtle.

• Week 1 to 2: The most commonly reported early effects are subtle training improvements, slightly fuller muscle pumps during workouts, and early water retention that makes muscles appear fuller. Some users notice reduced breathlessness under training load and a modest improvement in between-session recovery. Effects are establishing at this stage rather than fully arrived.
• Week 3 to 4: Recovery between sessions becomes more consistently noticeable. Mild body composition changes, primarily a leaner or fuller appearance, begin to emerge. The initial lethargy that some users report in the first two weeks typically lessens. Strength gains begin to feel more consistent in training, though individual variation is significant at this stage.
• Week 5 to 8: The protocol is at or approaching the maintenance level, and this is typically where the more meaningful cycle effects accumulate. Recovery patterns stabilize, training performance improvements become consistent, and body composition changes become more visible. This is also the phase where side effects can become more pronounced: carpal tunnel-like numbness or tingling in the hands, persistent water retention, and in some users sleep disruption appearing around weeks eight and nine.
• Beyond 8 weeks: Users who extend to 12 or 16 weeks report continued recovery and body composition benefits, particularly for injury-focused protocols. Sleep disruption, if it emerges, sometimes prompts a shift in injection timing or a step back in the titration during this later window.

These are commonly reported ranges drawn from real-world protocol logs across many users. Individual results vary by starting point, goal, cycle length, and consistency. A well-run 12-week cycle for a body composition or recovery goal commonly follows a progressive arc: the first four weeks establishing the foundation, weeks five through eight delivering the most noticeable change, and the final weeks consolidating those gains. Users who work through the titration without rushing, respect the fasted-injection timing principle, and treat tolerability signals as information rather than obstacles to push past commonly report a more favorable balance of results and side-effect management across the full cycle.

Common Protocol Mistakes

Eating before injection. The fasted-state principle is one of the most commonly ignored aspects of a CJC-1295 DAC protocol, and ignoring it costs meaningfully in terms of what each injection delivers. Injecting after carbohydrates spikes insulin in a way that directly blunts GH signaling. The 90 to 120 minute pre-injection fasting window is not arbitrary; it is the practical way to get the GH-releasing effect each dose is capable of.

Rushing the titration. The gradual ramp-up exists because of the long half-life, not in spite of it. Each dose stays active for more than a week, so escalating too quickly means stacking effects from multiple dose levels simultaneously before understanding how the body responds to any single one of them. Users who skip titration steps to reach the maintenance level faster frequently encounter side effects that then persist for a week or more. Moving to the next step every two weeks, and holding when a step produces a strong response, is how the protocol is designed to be run.

Ignoring side-effect signals. Flushing, pronounced water retention, hand tingling, and sleep disruption are not signals to push through. They indicate that the current dose level warrants holding rather than escalating. Unlike many peptides where a dose reduction provides relief within hours, a reduction here takes a week or more to produce a meaningful change in how the user feels.

Skipping off-cycle breaks. Continuous use is tempting when a cycle is going well, but the receptor desensitization that accumulates without breaks progressively blunts efficacy. The 4 to 6 week off-cycle period is what preserves the response in subsequent cycles. Users who run continuously commonly report diminishing returns over time, which is consistent with the desensitization mechanism.

Doubling up on missed injections. Given the 6 to 8 day half-life, a missed injection leaves substantial active compound still circulating from the previous dose. Adding an extra injection to compensate is unnecessary and increases side-effect burden without benefit. Resume the normal schedule at the next planned injection time without doubling up.

Using inadequately sourced product. Because CJC-1295 DAC is not available through the standard pharmaceutical supply chain, product purity, concentration accuracy, and sterility vary significantly across suppliers. Peptides sourced without third-party testing and verifiable manufacturing standards carry contamination and dosing accuracy risks that compound the inherent risks of a compound that stays active for a week per injection. Independent testing and verifiable manufacturing standards are the minimum bar for product quality.

Frequently Asked Questions

How long is a typical CJC-1295 DAC cycle?

Standard cycles run 8 to 12 weeks in the active phase, with some protocols extending to 16 weeks for recovery-focused or longevity applications. After each active cycle, a 4 to 6 week off-cycle break is standard before starting another run.

How often do you take CJC-1295 DAC?

Twice weekly is the most commonly cited frequency, with injections spaced 3 to 4 days apart, for example Monday and Thursday. This schedule works because the compound's half-life of roughly 6 to 8 days keeps each injection active in the body for well over a week. Some protocols use once weekly, though twice weekly is the more standard pattern across practitioner and community sources.

Does CJC-1295 DAC need a loading phase?

Not in the traditional sense. Rather than opening with a higher dose that drops to maintenance, CJC-1295 DAC protocols use a gradual upward titration that starts lower and steps up incrementally every two weeks until reaching the maintenance level. The purpose is to let the body adapt to continuous GH elevation before reaching the full target level, which is especially important given how long each injection stays active.

Do you need to cycle off CJC-1295 DAC?

Yes, and the rationale is well-established. A 4 to 6 week off-cycle break after each active cycle allows GH receptors to reset and regain sensitivity, lets GH and IGF-1 levels return toward baseline, and helps manage the immunological considerations associated with the DAC formulation's albumin-binding mechanism. Continuous use without breaks leads to progressively diminishing returns as receptors desensitize.

How does CJC-1295 DAC compare to the non-DAC version?

The core difference is half-life and injection pattern. The DAC version's half-life of roughly 6 to 8 days allows twice-weekly dosing but produces continuous, non-pulsatile GH elevation. The non-DAC version clears in under an hour and requires multiple daily injections, but its GH release pattern is more pulsatile and closer to the body's natural rhythm. The DAC version offers convenience; the non-DAC version offers faster side-effect reversibility and a GH release pattern that more closely mimics endogenous physiology.

What side effects are most commonly reported with CJC-1295 DAC?

The most consistently reported side effects include water retention, transient flushing or warmth shortly after injection, carpal tunnel-like numbness or tingling in the hands as the cycle progresses, and sleep disruption in some users, particularly later in longer cycles. Because the compound stays active for roughly a week per injection, side effects that emerge cannot be resolved quickly by skipping a dose; they persist until the compound clears naturally.

Disclaimer

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world protocols for CJC-1295 DAC in one place.